CompletedPhase 3NCT00524758

Oculusgen (Ologen) Glaucoma MMC Control in Estonia

Studying NON RARE IN EUROPE: Primary adult open-angle glaucoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Pro Top & Mediking Company Limited
Principal Investigator
Kuldar Kaljurand, MD
University of Tartu
Intervention
ologen (oculusgen) collagen matrix(device)
Enrollment
20 enrolled
Eligibility
19 years · All sexes
Timeline
20072011

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00524758 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Primary adult open-angle glaucoma

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Primary adult open-angle glaucoma

← Back to all trials